| Literature DB >> 15653641 |
Yee Leng Yap1, David C L Lam, Girard Luc, Xue Wu Zhang, David Hernandez, Robin Gras, Elaine Wang, S W Chiu, Lap Ping Chung, W K Lam, David K Smith, John D Minna, Antoine Danchin, Maria P Wong.
Abstract
Gene transcription in a set of 49 human primary lung adenocarcinomas and 9 normal lung tissue samples was examined using Affymetrix GeneChip technology. A total of 3442 genes, called the set M AD, were found to be either up- or down-regulated by at least 2-fold between the two phenotypes. Genes assigned to a particular gene ontology term were found, in many cases, to be significantly unevenly distributed between the genes in and outside M AD. Terms that were overrepresented in M AD included functions directly implicated in the cancer cell metabolism. Based on their functional roles and expression profiles, genes in M AD were grouped into likely co-regulated gene sets. Highly conserved sequences in the 5 kb region upstream of the genes in these sets were identified with the motif discovery tool, MoDEL. Potential oncogenic transcription factors and their corresponding binding sites were identified in these conserved regions using the TRANSFAC 8.3 database. Several of the transcription factors identified in this study have been shown elsewhere to be involved in oncogenic processes. This study searched beyond phenotypic gene expression profiles in cancer cells, in order to identify the more important regulatory transcription factors that caused these aberrations in gene expression.Entities:
Mesh:
Substances:
Year: 2005 PMID: 15653641 PMCID: PMC546166 DOI: 10.1093/nar/gki188
Source DB: PubMed Journal: Nucleic Acids Res ISSN: 0305-1048 Impact factor: 16.971
Figure 1Histogram of the cancer associated genes (MAD) correlation to the tissue labels (normal or lung adenocarcinomas). The average histograms generated from 10 separate random permutations of the cancer labels in the original lung adenocarcinoma dataset is also displayed.
Genes that were identified to be down- or up-regulated in adenocarcinomas
| Gene description (Gene down-regulated in lung AD) | Probe set | Fold log(AD/N) | Mean expression for normal lung | Mean expression for AD lung |
|---|---|---|---|---|
| Consensus sequence for Homo sapiens mRNA for receptor for Advanced Glycation End Product (RAGE) | 217046_s_at | −5.523 | 942.82 | 20.51 |
| Homo sapiens fatty acid binding protein 4, adipocyte (FABP4) | 203980_at | −4.768 | 3365.42 | 123.48 |
| Human alpha-globin gene with flanks | 217414_x_at | −4.419 | 9787.41 | 457.42 |
| Homo sapiens mRNA; cDNA DKFZp564N0582 (from clone DKFZp564N0582) | 209074_s_at | −4.294 | 678.28 | 34.58 |
| Homo sapiens carbonic anhydrase IV (CA4) | 206208_at | −4.276 | 275.78 | 14.24 |
| Homo sapiens RAGE mRNA for advanced glycation endproducts receptor, whole CDS | 210081_at | −4.261 | 1593.08 | 83.06 |
| Homo sapiens ficolin (collagen fibrinogen domain-containing) 3 (Hakata antigen) (FCN3) | 205866_at | −4.166 | 1790.33 | 99.70 |
| Human sickle cell beta-globin mRNA | 209116_x_at | −4.155 | 14733.26 | 827.29 |
| Consensus includes gb:BF939489 | 209469_at | −4.028 | 330.68 | 20.27 |
| Homo sapiens hemoglobin, gamma A (HBG1) | 204848_x_at | −3.922 | 264.79 | 17.47 |
| Homo sapiens adipose specific 2 (APM2) | 203571_s_at | −3.898 | 3042.43 | 204.08 |
| Homo sapiens hypothetical protein FLJ10970 (FLJ10970) | 219230_at | −3.884 | 1521.30 | 103.06 |
| Consensus includes gb:T50399/UG=Hs.251577 hemoglobin, alpha 1 | 214414_x_at | −3.874 | 13447.88 | 917.38 |
| Homo sapiens colony stimulating factor 3 (granulocyte) (CSF3) | 207442_at | −3.873 | 145.31 | 9.92 |
| Homo sapiens mutant beta-globin (HBB) gene | 217232_x_at | −3.864 | 15087.91 | 1036.22 |
| Gene description (Gene up-regulated in lung AD) | Probe Set | Fold log(AD/N) | ||
| Homo sapiens XAGE-1 protein (XAGE-1) | 220057_at | 7.311 | 4.79 | 760.58 |
| Human alpha-1 type XI collagen (COL11A1) | 37892_at | 6.208 | 6.10 | 451.07 |
| Consensus includes gb:AI697108;/UG=Hs.102482 mucin 5, subtype B, tracheobronchial | 213432_at | 6.192 | 4.84 | 354.11 |
| Homo sapiens dipeptidyl peptidase IV (DPP4) | 203716_s_at | 5.932 | 6.81 | 415.78 |
| Consensus includes gb:AU159942;/UG=Hs.156346 topoisomerase (DNA) II alpha (170 kDa) | 201291_s_at | 5.620 | 3.24 | 159.61 |
| Homo sapiens serine protease inhibitor, Kazal type 1 (SPINK1);/UG=Hs.181286 serine protease inhibitor, Kazal type 1 | 206239_s_at | 5.274 | 51.74 | 2002.30 |
| Consensus includes gb:X98568;/UG=Hs.179729 collagen, type X, alpha 1 (Schmid metaphyseal chondrodysplasia) | 217428_s_at | 4.991 | 21.98 | 698.84 |
| Consensus includes gb:AW192795;/UG=Hs.103707 apomucin | 214303_x_at | 4.969 | 5.26 | 164.65 |
| Human nephropontin mRNA;/UG=Hs.313 secreted phosphoprotein 1 (osteopontin, bone sialoprotein I, early T-lymphocyte activation 1) | 209875_s_at | 4.851 | 121.29 | 3499.34 |
| Homo sapiens matrix metalloproteinase 1 (interstitial collagenase) (MMP1) | 204475_at | 4.806 | 25.07 | 701.09 |
| Homo sapiens neuromedin U (NMU) | 206023_at | 4.776 | 5.80 | 158.88 |
| Homo sapiens cytokine receptor-like factor 1 (CRLF1) | 206315_at | 4.737 | 14.22 | 379.16 |
| Homo sapiens, serine (or cysteine) proteinase inhibitor, clade B (ovalbumin), member 3 | 209720_s_at | 4.597 | 2.13 | 51.63 |
| Homo sapiens multidrug resistance-associated protein homolog MRP3 (MRP3);/UG=Hs.90786 ATP-binding cassette, sub-family C (CFTRMRP), member 3 | 209641_s_at | 4.570 | 14.73 | 350.01 |
| Consensus includes gb:BE791251;/UG=Hs.25640 claudin 3 | 203953_s_at | 4.462 | 6.82 | 150.39 |
The description of each gene, its probe set in HG-U133A GeneChip and log fold change are given in the table. The complete table can be downloaded at .
The gene ontology terms overrepresented in the set of genes down-regulated by at least 2-fold in adenocarcinomas
| Annotation term | Total | Found | Expected | |
|---|---|---|---|---|
| GeneOntology terms | ||||
| Globin | 17 | 12 | 0.0E+00 | 0.0E+00 |
| Rhodopsin-like receptor activity | 384 | 49 | 3.8E−04 | 1.0E−06 |
| G-protein chemoattractant receptor activity | 34 | 8 | 2.8E−02 | 8.4E−04 |
| Peptide receptor activity | 139 | 23 | 1.7E−03 | 1.2E−05 |
| G-protein-coupled receptor binding | 52 | 21 | 0.0E+00 | 0.0E+00 |
| Defense/immunity protein activity | 230 | 39 | 0.0E+00 | 0.0E+00 |
| Antimicrobial peptide activity | 32 | 8 | 1.7E−02 | 5.4E−04 |
| Complement activity | 32 | 8 | 1.7E−02 | 5.4E−04 |
| Signal transducer activity | 2558 | 253 | 0.0E+00 | 0.0E+00 |
| Receptor activity | 1542 | 162 | 0.0E+00 | 0.0E+00 |
| Transmembrane receptor activity | 1083 | 121 | 0.0E+00 | 0.0E+00 |
| G-protein coupled receptor activity | 467 | 61 | 0.0E+00 | 0.0E+00 |
| Chemokine receptor activity | 34 | 8 | 2.8E−02 | 8.4E−04 |
| Receptor binding | 592 | 72 | 0.0E+00 | 0.0E+00 |
| Cytokine activity | 253 | 39 | 0.0E+00 | 0.0E+00 |
| Heavy metal binding | 23 | 8 | 9.4E−04 | 4.1E−05 |
| Sugar binding | 132 | 28 | 0.0E+00 | 0.0E+00 |
| Extracellular | 1085 | 138 | 0.0E+00 | 0.0E+00 |
| Extracellular space | 457 | 72 | 0.0E+00 | 0.0E+00 |
| Hemoglobin complex | 18 | 12 | 0.0E+00 | 0.0E+00 |
| Plasma membrane | 2297 | 219 | 0.0E+00 | 0.0E+00 |
| Integral to plasma membrane | 1702 | 176 | 0.0E+00 | 0.0E+00 |
| Oxygen and reactive oxygen species metabolism | 65 | 15 | 4.6E−04 | 7.0E−06 |
| Calcium ion homeostasis | 26 | 8 | 2.9E−03 | 1.1E−04 |
| Cell motility | 414 | 50 | 1.2E−03 | 3.0E−06 |
| Chemotaxis | 133 | 39 | 0.0E+00 | 0.0E+00 |
| Muscle contraction | 202 | 25 | 1.3E−01 | 6.2E−04 |
| Response to stress | 1025 | 143 | 0.0E+00 | 0.0E+00 |
| Defense response | 1031 | 169 | 0.0E+00 | 0.0E+00 |
| Inflammatory response | 218 | 50 | 0.0E+00 | 0.0E+00 |
| Immune response | 950 | 153 | 0.0E+00 | 0.0E+00 |
| Humoral immune response | 235 | 38 | 0.0E+00 | 0.0E+00 |
| Antimicrobial humoral response (sensu Invertebrata) | 145 | 24 | 1.2E−03 | 8.0E−06 |
| Cellular defense response | 139 | 45 | 0.0E+00 | 0.0E+00 |
| Cell communication | 3667 | 326 | 0.0E+00 | 0.0E+00 |
| Cell adhesion | 658 | 84 | 0.0E+00 | 0.0E+00 |
| Heterophilic cell adhesion | 97 | 20 | 9.7E−05 | 1.0E−06 |
| Signal transduction | 2947 | 254 | 0.0E+00 | 0.0E+00 |
| Cell surface receptor linked signal transduction | 1124 | 117 | 0.0E+00 | 0.0E+00 |
| G-protein coupled receptor protein signaling pathway | 657 | 77 | 0.0E+00 | 0.0E+00 |
| Cytosolic calcium ion concentration elevation | 49 | 10 | 3.2E−02 | 6.5E−04 |
| Cell-cell signaling | 689 | 64 | 3.7E−01 | 5.4E−04 |
| Development | 1920 | 150 | 1.5E+00 | 8.1E−04 |
| Histogenesis and organogenesis | 125 | 18 | 7.5E−02 | 6.0E−04 |
| Muscle development | 167 | 27 | 5.0E−04 | 3.0E−06 |
| Respiratory gaseous exchange | 36 | 11 | 2.2E−04 | 6.0E−06 |
| Chemokine activity | 52 | 21 | 0.0E+00 | 0.0E+00 |
| Circulation | 142 | 22 | 7.2E−03 | 5.1E−05 |
| Peptide receptor activity/G-protein coupled | 139 | 23 | 1.7E−03 | 1.2E−05 |
| Response to external stimulus | 1591 | 210 | 0.0E+00 | 0.0E+00 |
| Response to biotic stimulus | 1126 | 179 | 0.0E+00 | 0.0E+00 |
| Response to wounding | 356 | 91 | 0.0E+00 | 0.0E+00 |
| Response to pest/pathogen/parasite | 596 | 123 | 0.0E+00 | 0.0E+00 |
| Response to bacteria | 19 | 6 | 1.3E−02 | 7.1E−04 |
| Response to abiotic stimulus | 577 | 71 | 0.0E+00 | 0.0E+00 |
| Morphogenesis | 1119 | 101 | 4.9E−02 | 4.4E−05 |
| Organogenesis | 1029 | 91 | 2.2E−01 | 2.2E−04 |
| Cellular process | 7140 | 534 | 0.0E+00 | 0.0E+00 |
| Membrane | 4225 | 356 | 0.0E+00 | 0.0E+00 |
| Integral to membrane | 3220 | 281 | 0.0E+00 | 0.0E+00 |
| Cell growth | 97 | 17 | 7.3E−03 | 7.5E−05 |
| Humoral defense mechanism (sensu Invertebrata) | 145 | 24 | 1.2E−03 | 8.0E−06 |
| Cell–cell adhesion | 220 | 30 | 6.8E−03 | 3.1E−05 |
| Antimicrobial humoral response | 145 | 24 | 1.2E−03 | 8.0E−06 |
| Cytolysis | 20 | 8 | 2.4E−04 | 1.2E−05 |
| Cytokine binding | 80 | 14 | 2.6E−02 | 3.2E−04 |
| Chemokine binding | 34 | 8 | 2.8E−02 | 8.4E−04 |
| Carbohydrate binding | 133 | 28 | 0.0E+00 | 0.0E+00 |
| Chemoattractant activity | 52 | 21 | 0.0E+00 | 0.0E+00 |
| Response to chemical substance | 206 | 48 | 0.0E+00 | 0.0E+00 |
| Peptide binding | 213 | 26 | 1.3E−01 | 6.1E−04 |
| Taxis | 133 | 39 | 0.0E+00 | 0.0E+00 |
| Chemokine receptor binding | 52 | 21 | 0.0E+00 | 0.0E+00 |
| Innate immune response | 220 | 50 | 0.0E+00 | 0.0E+00 |
| Eicosanoid biosynthesis | 25 | 7 | 1.4E−02 | 5.7E−04 |
| Protein domain | ||||
| Vertebrate metallothionein | 12 | 7 | 2.4E−05 | 2.0E−06 |
| Aspartic acid and asparagine hydroxylation site | 143 | 21 | 3.5E−02 | 2.5E−04 |
| Rhodopsin-like GPCR superfamily | 289 | 42 | 0.0E+00 | 0.0E+00 |
| Endothelin receptor | 6 | 4 | 1.3E−03 | 2.1E−04 |
| Small chemokine, C-C subfamily | 26 | 11 | 0.0E+00 | 0.0E+00 |
| Fos transforming protein | 13 | 6 | 9.5E−04 | 7.3E−05 |
| Thrombospondin, type I | 52 | 13 | 7.8E−04 | 1.5E−05 |
| Globin | 16 | 12 | 0.0E+00 | 0.0E+00 |
| Small chemokine, C-X-C subfamily | 18 | 6 | 1.1E−02 | 6.0E−04 |
| C-type lectin | 95 | 19 | 5.7E−04 | 6.0E−06 |
| Alpha crystallin | 8 | 4 | 7.2E−03 | 9.0E−04 |
| Myelin proteolipid protein (PLP) | 7 | 6 | 0.0E+00 | 0.0E+00 |
| Zn-binding protein, LIM | 95 | 18 | 2.2E−03 | 2.3E−05 |
| Small chemokine, interleukin-8 like | 48 | 20 | 0.0E+00 | 0.0E+00 |
| EGF-like calcium-binding | 147 | 21 | 5.3E−02 | 3.6E−04 |
| Heat shock protein Hsp20 | 8 | 4 | 7.2E−03 | 9.0E−04 |
| Fibrinogen, beta/gamma chain, C-terminal globular | 38 | 10 | 3.4E−03 | 8.9E−05 |
| P2 purinoceptor | 21 | 7 | 4.3E−03 | 2.1E−04 |
| Myoglobin | 9 | 6 | 3.6E−05 | 4.0E−06 |
| Beta haemoglobin | 8 | 7 | 0.0E+00 | 0.0E+00 |
| Alpha haemoglobin | 6 | 5 | 3.6E−05 | 6.0E−06 |
| Pi haemoglobin | 6 | 5 | 3.6E−05 | 6.0E−06 |
| Small chemokine, C-X-C/Interleukin 8 | 18 | 8 | 1.1E−04 | 6.0E−06 |
| Metallothionein superfamily | 12 | 7 | 2.4E−05 | 2.0E−06 |
| Orphan nuclear receptor | 9 | 5 | 9.1E−04 | 1.0E−04 |
| Immunoglobulin C-2 type | 223 | 31 | 6.2E−03 | 2.8E−05 |
| Immunoglobulin subtype | 368 | 48 | 3.7E−04 | 1.0E−06 |
| PMP-22/EMP/MP20 family | 8 | 4 | 7.2E−03 | 9.0E−04 |
| L1 transposable element | 8 | 4 | 7.2E−03 | 9.0E−04 |
| EGF-like domain | 431 | 46 | 1.4E−01 | 3.3E−04 |
| Type I EGF | 169 | 23 | 6.7E−02 | 4.0E−04 |
| AIG1 family | 6 | 4 | 1.3E−03 | 2.1E−04 |
| BRICHOS domain | 13 | 8 | 0.0E+00 | 0.0E+00 |
| Immunoglobulin-like | 678 | 75 | 6.8E−04 | 1.0E−06 |
| LST-1 | 6 | 6 | 0.0E+00 | 0.0E+00 |
| Thrombospondin, subtype 1 | 27 | 8 | 5.0E−03 | 1.8E−04 |
| Saposin-like type B, 2 | 7 | 5 | 1.3E−04 | 1.9E−05 |
| Saposin B | 12 | 5 | 6.5E−03 | 5.4E−04 |
| Pathway | ||||
| GPCRs_Class_A_Rhodopsin-like | 212 | 34 | 0.0E+00 | 0.0E+00 |
| Peptide_GPCRs | 88 | 20 | 0.0E+00 | 0.0E+00 |
| MAP00590//Prostaglandin and leukotriene metabolism | 41 | 9 | 3.2E−02 | 7.7E−04 |
| GPCRs_Class_B_Secretin-like | 34 | 10 | 9.2E−04 | 2.7E−05 |
| Chromosomal location | ||||
| 12p | 301 | 32 | 2.4E−01 | 8.1E−04 |
| 8p21 | 117 | 18 | 1.8E−02 | 1.5E−04 |
| 17q23 | 68 | 14 | 2.2E−03 | 3.2E−05 |
| 16q13 | 37 | 12 | 3.7E−05 | 1.0E−06 |
For each gene ontology term, the total number of genes with this term in the HG-U133A GeneChip, the total number of genes carrying that term in MAD, the P-value of this and the expected number of genes are tabulated. The member genes for each gene ontology term can be downloaded at .
The gene ontology terms overrepresented in the set of genes up-regulated by at least 2-fold in adenocarcinomas
| Annotation term | Total | Found | Expected | |
|---|---|---|---|---|
| Gene Ontology term | ||||
| DNA replication and chromosome cycle | 233 | 54 | 0.0E+00 | 0.0E+00 |
| Cell cycle checkpoint | 50 | 17 | 5.5E−04 | 1.1E−05 |
| S phase of mitotic cell cycle | 183 | 38 | 1.1E−02 | 6.1E−05 |
| M phase of mitotic cell cycle | 149 | 46 | 0.0E+00 | 0.0E+00 |
| Nucleotide binding | 1737 | 235 | 2.1E−01 | 1.2E−04 |
| Mitotic cell cycle | 421 | 97 | 0.0E+00 | 0.0E+00 |
| M phase | 201 | 52 | 0.0E+00 | 0.0E+00 |
| Nuclear division | 195 | 50 | 0.0E+00 | 0.0E+00 |
| Chromatin | 117 | 29 | 1.8E−03 | 1.5E−05 |
| Nucleosome | 60 | 16 | 3.0E−02 | 5.0E−04 |
| Cytokinesis | 85 | 24 | 6.8E−04 | 8.0E−06 |
| Catalytic activity | 4887 | 638 | 0.0E+00 | 0.0E+00 |
| Carboxypeptidase A activity | 18 | 8 | 5.5E−03 | 3.1E−04 |
| Extracellular matrix structural constituent | 89 | 21 | 4.0E−02 | 4.5E−04 |
| Collagen | 54 | 23 | 0.0E+00 | 0.0E+00 |
| ATP binding | 1280 | 177 | 4.0E−01 | 3.1E−04 |
| Extracellular matrix | 345 | 65 | 2.1E−03 | 6.0E−06 |
| Collagen | 59 | 24 | 0.0E+00 | 0.0E+00 |
| Fibrillar collagen | 23 | 14 | 0.0E+00 | 0.0E+00 |
| Chromosome | 147 | 32 | 1.3E−02 | 8.8E−05 |
| Spindle | 64 | 21 | 1.3E−04 | 2.0E−06 |
| Intermediate filament | 76 | 19 | 2.9E−02 | 3.8E−04 |
| DNA metabolism | 606 | 97 | 3.1E−02 | 5.1E−05 |
| DNA replication | 178 | 36 | 2.9E−02 | 1.6E−04 |
| DNA dependent DNA replication | 94 | 23 | 1.3E−02 | 1.4E−04 |
| DNA replication initiation | 25 | 11 | 6.3E−04 | 2.5E−05 |
| Amino acid and derivative metabolism | 240 | 54 | 0.0E+00 | 0.0E+00 |
| Amino acid metabolism | 197 | 43 | 1.2E−03 | 6.0E−06 |
| Oncogenesis | 521 | 84 | 6.6E−02 | 1.3E−04 |
| Cell cycle | 871 | 145 | 0.0E+00 | 0.0E+00 |
| Chromosome segregation | 35 | 11 | 2.9E−02 | 8.4E−04 |
| Mitosis | 145 | 45 | 0.0E+00 | 0.0E+00 |
| Regulation of mitosis | 35 | 12 | 6.9E−03 | 2.0E−04 |
| Mitotic checkpoint | 16 | 7 | 1.3E−02 | 8.3E−04 |
| Ectoderm development | 98 | 26 | 1.1E−03 | 1.1E−05 |
| Cell proliferation | 1356 | 190 | 1.2E−01 | 8.9E−05 |
| Epidermal differentiation | 80 | 22 | 2.2E−03 | 2.8E−05 |
| Glutamine family amino acid metabolism | 46 | 15 | 2.9E−03 | 6.3E−05 |
| Amine metabolism | 283 | 60 | 0.0E+00 | 0.0E+00 |
| Histogenesis | 131 | 28 | 4.3E−02 | 3.3E−04 |
| Glucuronosyltransferase activity | 18 | 8 | 5.5E−03 | 3.1E−04 |
| Transferase activity | 1634 | 224 | 1.3E−01 | 8.1E−05 |
| Transferase activitytransferring glycosyl groups | 225 | 42 | 7.0E−02 | 3.1E−04 |
| Transferase activitytransferring hexosyl groups | 148 | 34 | 2.5E−03 | 1.7E−05 |
| Other carbon–nitrogen ligase activity | 25 | 9 | 2.1E−02 | 8.3E−04 |
| Purine nucleotide binding | 1723 | 233 | 2.3E−01 | 1.4E−04 |
| Adenyl nucleotide binding | 1292 | 179 | 3.4E−01 | 2.6E−04 |
| Intermediate filament cytoskeleton | 76 | 19 | 2.9E−02 | 3.8E−04 |
| Protein domain | ||||
| Fibrillar collagen, C-terminal | 23 | 14 | 0.0E+00 | 0.0E+00 |
| Endoplasmic reticulum targeting sequence | 76 | 19 | 2.0E−02 | 2.6E−04 |
| Epsin N-terminal homology | 16 | 7 | 1.1E−02 | 6.9E−04 |
| MCM family | 11 | 8 | 2.2E−05 | 2.0E−06 |
| Prolyl oligopeptidase | 12 | 6 | 8.6E−03 | 7.1E−04 |
| Intermediate filament protein | 67 | 17 | 3.0E−02 | 4.4E−04 |
| von Willebrand factor, type D | 9 | 6 | 7.7E−04 | 8.6E−05 |
| UDP-glucoronosyl/UDP-glucosyl transferase | 15 | 7 | 6.4E−03 | 4.3E−04 |
| Prolyl endopeptidase, serine active site | 8 | 5 | 4.4E−03 | 5.5E−04 |
| Immunoglobulin V-type | 146 | 32 | 6.3E−03 | 4.3E−05 |
| Cyclin, C-terminal | 19 | 9 | 1.0E−03 | 5.4E−05 |
| Disulphide isomerase | 12 | 7 | 8.4E−04 | 7.0E−05 |
| Cyclin | 44 | 14 | 4.7E−03 | 1.1E−04 |
| Cyclin, N-terminal domain | 34 | 12 | 3.7E−03 | 1.1E−04 |
| Histone core | 25 | 9 | 1.7E−02 | 6.7E−04 |
| Collagen triple helix repeat | 106 | 28 | 3.2E−04 | 3.0E−06 |
| Collagen helix repeat | 69 | 22 | 6.9E−05 | 1.0E−06 |
| Pathway | ||||
| Cell_cycle | 133 | 43 | 5.7E+00 | 4.3E−02 |
| Glutamate_metabolism | 27 | 12 | 3.2E−01 | 1.2E−02 |
| MAP00251//glutamate metabolism | 43 | 15 | 6.5E−01 | 1.5E−02 |
| Androgen_and_estrogen_metabolism | 15 | 7 | 1.1E−01 | 7.0E−03 |
| MAP00150//androgen and estrogen metabolism | 32 | 11 | 3.5E−01 | 1.1E−02 |
| Chromosomal location | ||||
| 7 | 961 | 129 | 8.7E−01 | 9.1E−04 |
| 1q | 920 | 126 | 4.4E−01 | 4.8E−04 |
| 8q | 388 | 67 | 5.8E−03 | 1.5E−05 |
Details are as described in Table 2.
Highly conserved DNA regions, detected with MoDEL, in regions 5 kb directly upstream of the transcription start site in putatively co-regulated gene sets
| Gene Ontology | Location | Frequency | Similar regulation | Putative transcription factors | |||
|---|---|---|---|---|---|---|---|
| Gene up-regulated in lung adenocarcinomas cells | |||||||
| DNA replication and chromosome cycle | |||||||
| NM 004526 | −2467 | 1 | 100% | Whn,AhR,GATA-1,PITX2,HIF-1 | |||
| NM 002916 | −2920 | 7 | 75% | MyoD,E47,AREB6,E12,USF,GATA-1,PITX2 | |||
| NM 003504 | −3179 | 1 | 100% | Whn,AhR,GATA-1,PITX2,Major,MyoD,E47,TFII-I,AREB6,TAL1,E12,USF,HIF-1 | |||
| Profile | |||||||
| Nuclear division | |||||||
| NM 004701 | −3735 | 1 | 100% | HES1,SREBP-1,TFII-I,DEC,USF,Nkx2-5,GATA-1 | |||
| NM 001211 | −3705 | 1 | 100% | TFII-I,Elk-1,NERF1a,c-Ets-1(p54),68,AREB6 | |||
| NM 020242 | −2016 | 1 | 100% | TAL1,HEB,TFII-I,Zta,c-Ets-1(p54),DEC,SREBP-1,USF,Nkx2-5,RORalpha1 | |||
| NM 022346 | −2071 | 1 | 100% | ||||
| NM 003981 | −866 | 1 | 100% | TFII-I,DEC,Nkx2-2,SREBP-1,USF,Nkx2-5,AREB6,HIF-1 | |||
| NM 001237 | −167 | 1 | 100% | ||||
| NM 001813 | −715 | 1 | 100% | TFII-I,Zta,DEC,Nkx2-2,SREBP-1,USF,TTF1,Nkx2-5,c-Ets-1,c-Ets-1(p54),AREB6 | |||
| NM 002358 | −4881 | 1 | 100% | TFII-I,C/EBPdelta,AREB6 | |||
| NM 022346 | −2071 | 1 | 100% | ||||
| Profile | |||||||
| Gene down-regulated in lung adenocarcinomas cells | |||||||
| Cellular defense response | |||||||
| NM 005874 | −715 | 1 | 100% | USF,AREB6,GR | |||
| NM 000265 | −3997 | 2 | 100% | RFX1,TFII-I,AREB6,DEC,SREBP-1,Nkx2-2,Nkx2-5,USF, HIF-1 | |||
| NM 016382 | −3907 | 1 | 100% | RFX1,TFII-I,AREB6,c-Ets-1(p54),GATA-1,DEC,TTF1,SREBP-1,Nkx2-2,Nkx2-5,USF,Zta | |||
| Profile | |||||||
| Signal transduction | |||||||
| NM 000459 | −2597 | 1 | 100% | Zta,c-Ets-1(p54),RFX1 | |||
| NM 005308 | −2401 | 1 | 100% | GATA-1,AREB6,RFX1 | |||
| NM 000115 | −1967 | 2 | 50% | TFII-I,Zta,DEC,SREBP-1,Nkx2-2,USF,Nkx2-5,AREB6,c-Ets-1(p54) | |||
| NM 005424 | −1039 | 1 | 100% | AREB6,v-Myb,MAZ,Hand1:E47 | |||
| NM 003991 | −340 | 1 | 100% | SMAD-3 | |||
| NM 005795 | −1930 | 1 | 100% | Zta,TFII-I,C/EBPdelta,c-Ets-1(p54),AREB6 | |||
| NM 003357 | −4624 | 1 | 100% | Zta,TFII-I,c-Ets-1(p54),AREB6,RFX1 | |||
| NM 005856 | −3601 | 3 | 100% | Zta,TFII-I,GATA-1,c-Ets-1(p54),AREB6,RFX1 | |||
| NM 004844 | −4824 | 3 | 100% | Zta,TFII-I,c-Ets-1(p54) | |||
| Profile | |||||||
The complete table can be downloaded at .
aOverrepresented gene ontology terms.
bLocation of conserved sequence upstream of the transcription start site.
cFrequency of occurrence of conserved sequence in 5 kb upstream regions of genes given in (32).
dPercentage of the genes with a matched upstream sequence and their expression trends.
eTranscription factor name from TRANSFAC (8.3) FACTOR table (35,73).